The DOI matches its Crossref record; 223 of the 223 references it cites were found in a registry or an index.
The Emerging Landscape of Immune Cell Therapies
Open accessAbstract
Cell therapies present an entirely new paradigm in drug development. Within this class, immune cell therapies are among the most advanced, having already demonstrated definitive evidence for clinical benefit in cancer and infectious disease. Numerous features distinguish these “living therapies” from traditional medicines, including their ability to expand and contract in proportion to need and to mediate therapeutic benefits for months or years following a single application. Continued advances in fundamental immunology, genetic engineering, gene editing, and synthetic biology exponentially expand opportunities to enhance the sophistication of T cell therapies, thereby increasing potency and safety and broadening their potential for treatment of disease. This perspective will summarize the current status of immune cell therapies for cancer, infectious disease, and autoimmunity, and discuss advances in cellular engineering currently under study to overcome barriers to progress.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–223 of 223
Leung, W., Gay, J. W., Martin, U., Garrett, T. E., Horton, H. M., Certo, M. T., Blazar, B. R., Morgan, R. A., Gregory, P. D., Jarjour, J., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.124430 · Cited by 88
Jones, S., Peng, P. D., Yang, S., Hsu, C., Cohen, C. J., Zhao, Y., Abad, J., Zheng, Z., Rosenberg, S. A., & Morgan, R. A. (2009) · Human Gene Therapy · doi:10.1089/hum.2008.048 · Cited by 84
CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia
Bonifant, C. L., Szöőr, Á., Torres, D., Joseph, N. P., Velasquez, M. P., Iwahori, K., Gaikwad, A. S., Nguyen, P., Arber, C., Song, X., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.116 · Cited by 84
Ormhøj, M., Scarfò, I., Cabral, M. L., Bailey, S. R., Lorrey, S., Bouffard, A. A., Castaño, A. P., Larson, R. C., Riley, L. S., Schmidts, A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1337 · Cited by 77
Self-citationThe Impact of TCR-Binding Properties and Antigen Presentation Format on T Cell Responsiveness
Chervin, A. S., Stone, J. D., Holler, P. D., Bai, A., Chen, J., Eisen, H. N., & Kranz, D. M. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900054 · Cited by 75
Ayala, V. I., Deléage, C., Trivett, M. T., Jain, S., Coren, L. V., Breed, M. W., Kramer, J. A., Thomas, J. A., Estes, J. D., Lifson, J. D., et al. (2017) · Journal of Virology · doi:10.1128/jvi.02507-16 · Cited by 74
Hart, D. P., Xue, S., Thomas, S., Cesco-Gaspere, M., Tranter, A., Willcox, B., Lee, S. P., Steven, N. M., Morris, E. C., & Stauss, H. J. (2008) · Gene Therapy · doi:10.1038/sj.gt.3303078 · Cited by 72
Framework engineering to produce dominant T cell receptors with enhanced antigen-specific function
Thomas, S., Mohammed, F., Reijmers, R. M., Woolston, A., Stauss, T., Kennedy, A., Stirling, D. R., Holler, A., Green, L., Jones, D. T., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12441-w · Cited by 68
Shared cancer neoantigens: Making private matters public
Klebanoff, C. A., & Wolchok, J. D. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20172188 · Cited by 67
Xiao, L., Chen, C., Li, Z., Zhu, S., Tay, J. C., Zhang, X., Zha, S., Zeng, J., Tan, W. K., Liu, C. X., et al. (2018) · Cytotherapy · doi:10.1016/j.jcyt.2017.12.014 · Cited by 65
Heitzeneder, S., Sotillo, E., Shern, J. F., Sindiri, S., Xu, P., Jones, R. C., Pollak, M., Noer, P. R., Lorette, J., Fazli, L., et al. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy209 · Cited by 63
Self-citationSchmitt, T. M., Aggen, D. H., Stromnes, I. M., Dossett, M. L., Richman, S. A., Kranz, D. M., & Greenberg, P. D. (2013) · Blood · doi:10.1182/blood-2013-01-478164 · Cited by 62
Abramson, J. S., Palomba, M. L., Gordon, L. I., Lunning, M. A., Arnason, J. E., Wang, M. L., Forero, A., Maloney, D. G., Albertson, T., Garcia, J., et al. (2017) · Blood · doi:10.1182/blood.v130.suppl_1.581.581 · Cited by 62
Deniger, D. C., Pasetto, A., Tran, E., Parkhurst, M. R., Cohen, C. J., Robbins, P. F., Cooper, L. J. N., & Rosenberg, S. A. (2016) · Molecular Therapy · doi:10.1038/mt.2016.51 · Cited by 59
Velasquez, M. P., Torres, D., Iwahori, K., Kakarla, S., Arber, C., Rodríguez-Cruz, T., Szöőr, Á., Bonifant, C. L., Gerken, C. P., Cooper, L. J. N., et al. (2016) · Scientific Reports · doi:10.1038/srep27130 · Cited by 59
Inducing and Administering Tregs to Treat Human Disease
Perdigoto, A. L., Chatenoud, L., Bluestone, J. A., & Herold, K. C. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00654 · Cited by 56
Schultz, L. M., Davis, K. L., Baggott, C., Chaudry, C., Marcy, A. C., Mavroukakis, S. A., Sahaf, B., Kong, K. A., Muffly, L. S., Kim, S. H., et al. (2018) · Blood · doi:10.1182/blood-2018-99-117445 · Cited by 52
Self-citationVoss, R.-H., Kuball, J. H. E., Engel, R., Guillaume, P., Romero, P. J., Huber, C., & Theobald, M. (2006) · Immunologic Research · doi:10.1385/ir:34:1:67 · Cited by 49
Shah, N. N., Zhu, F., Schneider, D., Taylor, C., Krueger, W. H., Worden, A., Longo, W., Hamadani, M., Fenske, T. S., Johnson, B. D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.2510 · Cited by 42
Bowerman, N. A., Crofts, T. S., Chlewicki, L. K., Do, P., Baker, B. M., García, K. C., & Kranz, D. M. (2009) · Molecular Immunology · doi:10.1016/j.molimm.2009.06.012 · Cited by 39
Bejestani, E. P., Cartellieri, M., Bergmann, R., Ehninger, A., Loff, S., Krämer, M., Spehr, J., Dietrich, A., Feldmann, A., Albert, S., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1342909 · Cited by 37
Weber, E. W., Lynn, R. C., Parker, K. R., Anbunathan, H., Lattin, J., Sotillo, E., Good, Z., Malipatlolla, M., Xu, P., Vandris, P., et al. (2020) · doi:10.1101/2020.01.26.920496 · Cited by 18 · cited 3×
“Finally, transient disruption of tonic CAR signaling via regulation of CAR protein can epigenetically repro- 54 Cell 181, April 2, 2020 gram exhausted CAR T cells and augment efficacy in pre-clinical models (Weber et al., 2020).”
BackgroundSelf-citationSharma, P. A., Harris, D. T., Stone, J. D., & Kranz, D. M. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0035 · Cited by 14
Cited by
Intratumoral heterogeneity in cancer progression and response to immunotherapy
Vitale, I., Shema, E., Loi, S., & Galluzzi, L. (2021) · Nature Medicine · doi:10.1038/s41591-021-01233-9 · Cited by 826
Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling
Weber, E. W., Parker, K. R., Sotillo, E., Lynn, R. C., Anbunathan, H., Lattin, J., Good, Z., Belk, J. A., Daniel, B., Klysz, D., et al. (2021) · Science · doi:10.1126/science.aba1786 · Cited by 607
Self-citationTherapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Wang, D.-R., Wu, X.-L., & Sun, Y.-L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01136-2 · Cited by 501
CD8+ T cells in the cancer-immunity cycle
Giles, J. R., Globig, A.-M., Kaech, S. M., & Wherry, E. J. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.005 · Cited by 449
Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
Gong, Y., Klein Wolterink, R. G. J., Wang, J., Bos, G. M. J., & Germeraad, W. T. V. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01083-5 · Cited by 379
Metadata
- Authors
- Weber, E. W., Maus, M. V., & Mackall, C. L.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 181
- Issue
- 1
- Pages
- 46-62
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W3015123349
- Cited by
- 446
- References
- 223
- FWCI
- 20.37
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.